Literature DB >> 11959380

Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity.

Alf Inge Larsen1, Sigurd Lindal, Pål Aukrust, Ingrid Toft, Torbjørn Aarsland, Kenneth Dickstein.   

Abstract

BACKGROUND: In patients with congestive heart failure (CHF) there is a shift from aerobic type I muscle fibres to less aerobic type II fibres. Exercise training has been shown to have beneficial effects on exercise performance, peripheral pathology and the neurohumoral profile in stable patients with CHF. This study evaluated the effect of a 3 month exercise training program on skeletal muscle characteristics and the correlation of these to cytokines and exercise capacity in CHF patients.
METHODS: Skeletal muscle biopsies for enzyme-histochemical analysis were performed in 15 CHF patients in New York Heart Association classes II-III, with a mean ejection fraction of 33+/-5% before and after a 12 week training period. The patients were trained for 30 min, five times a week at 80% of the peak heart rate achieved at baseline ergometer cycle test. Fifteen healthy men were used as controls. Plasma samples were examined by enzyme immunoassays for levels of pro-inflammatory cytokines.
RESULTS: (a) At baseline we found muscle atrophy in five of the patients. The percent area of type I fibres (40.7+/-12.0 vs. 56.4+/-11.0%, P<0.05) and the thickness of type IIA (56.10+/-7.8 vs. 71.6+/-11.9 microm, P<0.001) and B-fibres (49.0+/-8.9 vs. 63.9+/-10.6 microm, P<0.001) were reduced, whereas the percent area of type IIA fibres (52.1+/-13.3 vs. 36.4+/-9.9%, P<0.05) was increased in heart failure patients compared to healthy controls. There was a modest correlation between fibre thickness and the level of interleukin 6 (r=-0.657, P=0.008). (b) After exercise training there was a reduction in muscle area examined by light-microscopy, measured as a percentage of field (-2.7, P=0.003) with an concomitant increase in interstitium. This reduction correlated to the increase in the 6-min walk test (r=-0.558, P=0.031). The thickness of type IIB fibres increased (+5.6 microm, P=0.068) and the area of type I fibres decreased (-6.1%, P=0.062).
CONCLUSIONS: Patients with CHF have a relatively increased area of type IIA fibres and a relatively decreased area of type I fibres compared to healthy individuals. The thickness of type IIA and type IIB fibres is decreased compared to normal individuals. A modest negative correlation between the level of interleukin 6 and fibre thickness at baseline, suggests that inflammatory cytokines may be involved in the pathogenesis of the CHF related myopathy. A significant correlation between the reduction of muscle area, with increased interstitum, and the increase in the 6-min walk test may indicate that the improvement is due to increased capillary density permitting better flow reserve to exercising muscles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959380     DOI: 10.1016/s0167-5273(02)00014-1

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  19 in total

Review 1.  Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure.

Authors:  Holly R Middlekauff
Journal:  Circ Heart Fail       Date:  2010-07       Impact factor: 8.790

Review 2.  Mechanisms by which exercise training benefits patients with heart failure.

Authors:  Ettore Crimi; Louis J Ignarro; Francesco Cacciatore; Claudio Napoli
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

Review 3.  Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction.

Authors:  Bharathi Upadhya; Mark J Haykowsky; Joel Eggebeen; Dalane W Kitzman
Journal:  Curr Heart Fail Rep       Date:  2015-06

4.  [Individualization of exercise load control for inpatient cardiac rehabilitation. Development and evaluation of a HRV-based intervention program for patients with ischemic heart failure].

Authors:  K Behrens; K Hottenrott; M Weippert; H Montanus; S Kreuzfeld; A Rieger; J Lübke; K Werdan; R Stoll
Journal:  Herz       Date:  2014-01-19       Impact factor: 1.443

5.  Investigating activity in hospitalized patients with chronic obstructive pulmonary disease: a pilot study.

Authors:  Chris Winkelman
Journal:  Heart Lung       Date:  2010-04-08       Impact factor: 2.210

6.  The role of exercise therapy in the treatment of patients with systolic heart failure.

Authors:  Andrew Kao
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

7.  Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction.

Authors:  Dalane W Kitzman; Barbara Nicklas; William E Kraus; Mary F Lyles; Joel Eggebeen; Timothy M Morgan; Mark Haykowsky
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-21       Impact factor: 4.733

Review 8.  Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training.

Authors:  Brian D Duscha; P Christian Schulze; Jennifer L Robbins; Daniel E Forman
Journal:  Heart Fail Rev       Date:  2008-02       Impact factor: 4.214

9.  Effect of exercise training on cardiovascular autonomic and muscular function in subclinical Chagas cardiomyopathy: a randomized controlled trial.

Authors:  Adriana Oliveira Sarmento; Ligia M Antunes-Correa; Maria J N N Alves; Aline V N Bacurau; Keila C B Fonseca; Fernanda G Pessoa; Denise M L Lobo; Leila D P Moreira; Ivani C Trombetta; Maria U P B Rondon; Eduardo Rondon; Marcelo L C Vieira; Felix J A Ramires; Maria Socorro do Brasileiro-Santos; Patricia C Brum; Charles Mady; Carlos E Negrao; Scott Thomas; Barbara M Ianni
Journal:  Clin Auton Res       Date:  2020-09-01       Impact factor: 4.435

10.  Chronic heart failure and exercise intolerance: the hemodynamic paradox.

Authors:  Kent R Nilsson; Brian D Duscha; Patrick M Hranitzky; William E Kraus
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.